ELSEVIER

Journal of Affective Disorders 49 (1998) 251–253

JOURNAL OF AFFECTIVE DISORDERS

Author index

Abrams, M., see Cook, I.A. (49) 89
Allicar, M.P., see Bouhassira, M. (49) 19
Altshuler, L., see McElroy, S.L. (49) 119
Amsterdam, J.D., see Hornig, M. (49) 9
Andersen, P.K., see Kessing, L.V. (49) 101
Andrews, W., Parker, G. and Barrett, E.
The SSRI antidepressants: Exploring their "other" possible properties (49) 141
Auerbach, M., see Gladsjo, J.A. (49) 123

Balan, S., Spivak, B., Mester, R., Leibovitz, A., Habot, B. and Weizman, A.
Psychiatric and polysomnographic evaluation of sleep disturbances (49) 27
Barbini, B., see Benedetti, F. (49) 133
Barrett, E., see Andrews, W. (49) 141
Baumann, P., Nil, R., Bertschy, G., Jecker, A., Brändli, H., Morand, J., Kasas, A., Vuagniaux, O. and Ramseier, F.
A double-blind double-dummy study of citalopram comparing infusion versus oral administration (49) 203
Beattie, J.A.G., see Eagles, J.M. (49) 1
Benedetti, F., Barbini, B., Campori, E., Colombo, C. and Smeraldi, E.
Patterns of mood variation during antidepressant treatment (49) 133
Bertschy, G., see Baumann, P. (49) 203
Blachier, C., see Bouhassira, M. (49) 19
Blackburn, I.-M., see Gloaguen, V. (49) 59
Bonaccorso, S., see Song, C. (49) 211
Bosmans, E., see Song, C. (49) 211
Bouhassira, M., Allicar, M.P., Blachier, C., Nouveau, A. and Rouillon, F.
Which patients receive antidepressants? A 'real world' telephone study (49) 19
Bousquet, A., see Righetti-Veltema, M. (49) 167
Bouwer, C. and Stein, D.J.
Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia (49) 79
Brändli, H., see Baumann, P. (49) 203

Campori, E., see Benedetti, F. (49) 133
Christie, J., see Eagles, J.M. (49) 1
Colombo, C., see Benedetti, F. (49) 133
Conne-Perréard, E., see Righetti-Veltema, M. (49) 167
Cook, I.A., Leuchter, A.F., Uijtdehaage, S.H.J., Osato, S., Holschneider, D.H., Abrams, M. and Rosenberg-Thompson, S.
Altered cerebral energy utilization in late life depression (49) 89
Cooke, R.G., see Robb, J.C. (49) 189
Coryell, W.H., see Dawson, R. (49) 31
Cosyns, P., see Song, C. (49) 211
Cottraux, J., see Gloaguen, V. (49) 59
Cucherat, M., see Gloaguen, V. (49) 59
Cuesta, M.J., see Peralta, V. (49) 55

Davis, J., see Gladsjo, J.A. (49) 123
Dawson, R., Lavori, P.W., Coryell, W.H., Endicott, J. and Keller, M.B.
Maintenance strategies for unipolar depression: an observational study of levels of treatment and recurrence (49) 31
de Jongh, R., see Song, C. (49) 211
Denicoff, K., see McElroy, S.L. (49) 119
Dramaix, M., see Fossion, P. (49) 181

Eagles, J.M., Naji, S.A., Gray, D.A., Christie, J. and Beattie, J.A.G.
Seasonal affective disorder among primary care consulters in January: Prevalence and month by month consultation patterns (49) 1
Ehlers, A.
Why Van der Does, Van Dyck and Spinhoven (1997) did not demonstrate that superior heartbeat perception in panic disorder is partly an artefact (49) 241
Ekman, R., see Westrin, Å (49) 45
Endicott, J., see Dawson, R. (49) 31
Engström, G., see Westrin, Å (49) 45

Fong, S., see Lee, S. (49) 73
Fossion, P., Staner, L., Dramaix, M., Kempenaers, Ch., Kerkhofs, M., Hubain, Ph., Verbanck, P., Mendlewicz, J. and Linkowski, P.
Does sleep EEG data distinguish between UP, BPI or BPII major depressions? An age and gender controlled study (49) 181
Frye, M., see McElroy, S.L. (49) 119

Gladsjo, J.A., Rapaport, M.H., McKinney, R., Lucas, J.A., Rabin, A., Oliver, T., Davis, J., Auerbach, M. and Judd, L.L.

S0165-0327(98)00044-5

A neuropsychological study of panic disorder: Negative findings (49) 123
Gloaguen, V., Cottraux, J., Cucherat, M. and Blackburn, I.-M.
A meta-analysis of the effects of cognitive therapy in depressed patients (49) 59
Goodman, D.B.P., see Hornig, M. (49) 9
Gray, D.A., see Eagles, J.M. (49) 1
Griez, E., see Verburg, K. (49) 195

Habot, B., see Balan, S. (49) 27
Heide, C., see Song, C. (49) 211
Holschneider, D.H., see Cook, I.A. (49) 89
Hornig, M., Goodman, D.B.P., Kamoun, M. and Amsterdam, J.D.
Positive and negative acute phase proteins in affective subtypes (49) 9
Hubain, Ph., see Fossion, P. (49) 181
Hünerjäger, H., see Staedt, J. (49) 221

Jecker, A., see Baumann, P. (49) 203
Joffe, R.T., see Robb, J.C. (49) 189
Judd, L.L., see Gladsjo, J.A. (49) 123

Kamoun, M., see Hornig, M. (49) 9
Kasas, A., see Baumann, P. (49) 203
Keck, Jr., P.E., see McElroy, S.L. (49) 119
Keller, M.B., see Dawson, R. (49) 31
Kempenaers, Ch., see Fossion, P. (49) 181
Kenis, G., see Song, C. (49) 211
Kerkhofs, M., see Fossion, P. (49) 181
Kessing, L.V., Andersen, P.K. and Mortensen, P.B.
Predictors of recurrence in affective disorder. A case register study (49) 101
Klaassen, T., see Verburg, K. (49) 195
Kmetz, G.F., see McElroy, S.L. (49) 119
Knoll, J., Stegman, K. and Suppes, T.
Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania (49) 229
Kripke, D.F.
Light treatment for nonseasonal depression: speed, efficacy, and combined treatment (49) 109
Kupka, R., see McElroy, S.L. (49) 119

Lahdelma, L., see Spoov, J. (49) 235
Lam, R.W., see Shiah, I.-S. (49) 157
Lavori, P.W., see Dawson, R. (49) 31
Lee, S., Wing, Y.K. and Fong, S.
A controlled study of folate levels in Chinese inpatients with major depression in Hong Kong (49) 73
Leibovitz, A., see Balan, S. (49) 27
Leuchter, A.F., see Cook, I.A. (49) 89
Leverich, G.S., see McElroy, S.L. (49) 119
Lin, A., see Song, C. (49) 211
Linkowski, P., see Fossion, P. (49) 181
Lucas, J.A., see Gladsjo, J.A. (49) 123

Maes, M., see Song, C. (49) 211
Manzano, J., see Righetti-Veltema, M. (49) 167
McElroy, S.L., Frye, M., Denicoff, K., Altshuler, L., Nolen, W., Kupka, R., Suppes, T., Keck, Jr., P.E., Leverich, G.S., F. Kmetz, G. and Post, R.M.
Olanzapine in treatment-resistant bipolar disorder (49) 119
McKinney, R., see Gladsjo, J.A. (49) 123
Mendlewicz, J., see Fossion, P. (49) 181
Mester, R., see Balan, S. (49) 27
Morand, J., see Baumann, P. (49) 203
Mortensen, P.B., see Kessing, L.V. (49) 101

Naji, S.A., see Eagles, J.M. (49) 1
Nil, R., see Baumann, P. (49) 203
Nolen, W., see McElroy, S.L. (49) 119
Nouveau, A., see Bouhassira, M. (49) 19

Oliver, T., see Gladsjo, J.A. (49) 123
Osato, S., see Cook, I.A. (49) 89

Parker, G., see Andrews, W. (49) 141
Peralta, V. and Cuesta, M.J.
Lack of insight in mood disorders (49) 55
Pols, H., see Verburg, K. (49) 195
Post, R.M., see McElroy, S.L. (49) 119

Rabin, A., see Gladsjo, J.A. (49) 123
Ramseier, F., see Baumann, P. (49) 203
Rapaport, M.H., see Gladsjo, J.A. (49) 123
Reich, J.
The relationship of suicide attempts, borderline personality traits, and major depressive disorder in a veteran outpatient population (49) 151
Righetti-Veltema, M., Conne-Perréard, E., Bousquet, A. and Manzano, J.
Risk factors and predictive signs of postpartum depression (49) 167
Robb, J.C., Young, L.T., Cooke, R.G. and Joffe, R.T.
Gender differences in patients with bipolar disorder influence outcome in the medical outcomes survey (SF-20) subscale scores (49) 189
Rosenberg-Thompson, S., see Cook, I.A. (49) 89
Rouillon, F., see Bouhassira, M. (49) 19
Rüther, E., see Staedt, J. (49) 221

Scharpe, S., see Song, C. (49) 211
Sharma, M., see Srivastava, S. (49) 145
Shiah, I.-S., Yatham, L.N., Lam, R.W. and Zis, A.P.
Effects of lamotrigine on the 5-HT_{1A} receptor function in healthy human males (49) 157
Smeraldi, E., see Benedetti, F. (49) 133
Song, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., de Jongh, R. and Maes, M.
The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression (49) 211
Spinhoven, Ph., see Van der Does, A.J.W. (49) 245
Spivak, B., see Balan, S. (49) 27
Spoov, J. and Lahdelma, L.

Should thyroid augmentation precede lithium augmentation – a pilot study (49) 235
Srivastava, S. and Sharma, M.
Seasonal affective disorder: report from India (latitude 26° 45′N) (49) 145
Staedt, J., Hünerjäger, H., Rüther, E. and Stoppe, G.
Sleep cluster arousal analysis and treatment response to heterocyclic antidepressants in patients with major depression (49) 221
Staner, L., see Fossion, P. (49) 181
Stegman, K., see Knoll, J. (49) 229
Stein, D.J., see Bouwer, C. (49) 79
Stoppe, G., see Staedt, J. (49) 221
Suppes, T., see Knoll, J. (49) 229
Suppes, T., see McElroy, S.L. (49) 119

Träskman-Bendz, L., see Westrin, Å (49) 45

Uijtdehaage, S.H.J., see Cook, I.A. (49) 89

Van der Does, A.J.W., Van Dyck, R. and Spinhoven, Ph.
No heart feelings. Reply to Ehlers [J. Affect. Disord. 49 (1998) 241] (49) 245
Van Dyck, R., see Van der Does, A.J.W. (49) 245
Verbanck, P., see Fossion, P. (49) 181
Verburg, K., Klaassen, T., Pols, H. and Griez, E.
Comorbid depressive disorder increases vulnerability to the 35% carbon dioxide (CO_2) challenge in panic disorder patients (49) 195
Verkerk, R., see Song, C. (49) 211
Vuagniaux, O., see Baumann, P. (49) 203

Weizman, A., see Balan, S. (49) 27
Westrin, Å, Engström, G., Ekman, R. and Träskman-Bendz, L.
Correlations between plasma-neuropeptides and temperament dimensions differ between suicidal patients and healthy controls (49) 45
Whelan, A., see Song, C. (49) 211
Wing, Y.K., see Lee, S. (49) 73

Yatham, L.N., see Shiah, I.-S. (49) 157
Young, L.T., see Robb, J.C. (49) 189

Zis, A.P., see Shiah, I.-S. (49) 157

ELSEVIER

Journal of Affective Disorders 49 (1998) 255–257

JOURNAL OF AFFECTIVE DISORDERS

Subject index

Absent atypical vegetative symptoms; SAD; Tropical climate **49,** 145

Acute phase proteins; Affective disorders; C-reactive protein; Transferrin **49,** 9

Affective disorder; Unipolar; Bipolar; Case register; Longitudinal data; Recurrence; Predictors **49,** 101

Affective disorders; Acute phase proteins; C-reactive protein; Transferrin **49,** 9

Affective disorders; Suicide attempt; Temperament; Neuropeptides; Dexamethasone suppression test; Cortisol **49,** 45

Amino acids; Tryptophan; Cytokines; PGE2; Depression; Sleep disorders **49,** 211

Anticonvulsants; Bipolar disorder; Treatment; Mood lability; Gabapentin **49,** 229

Antidepressant; Pharmacoepidemiology; General population; Cross sectional survey; Prescription; Drug utilization review **49,** 19

Antidepressant; Light; Depression; Clinical trials **49,** 109

Antidepressant response; Major depression; Sleep; Arousalanalysis **49,** 221

Antidepressants; Cognitive therapy; Behaviour therapy; Depression; Meta-analysis; Psychotherapy **49,** 59

Antidepressants; Depression; SSRI; Treatment **49,** 141

Anxiety; Panic disorder; Neuropsychology **49,** 123

Arousalanalysis; Major depression; Antidepressant response; Sleep **49,** 221

Augmentation; Depression; Lithium; Thyroxine **49,** 235

Behaviour therapy; Cognitive therapy; Depression; Meta-analysis; Psychotherapy; Antidepressants **49,** 59

Bipolar; Affective disorder; Unipolar; Case register; Longitudinal data; Recurrence; Predictors **49,** 101

Bipolar I; Unipolar; Bipolar II major depression; Sleep EEG data; Newcastle rating scale; REM-sleep; REM-latency **49,** 181

Bipolar II major depression; Unipolar; Bipolar I; Sleep EEG data; Newcastle rating scale; REM-sleep; REM-latency **49,** 181

Bipolar disorder; Olanzapine **49,** 119

Bipolar disorder; Gender differences; Depression; Well-being and functioning; Course of illness; Outcome; Physical health; Pain **49,** 189

Bipolar disorder; Treatment; Anticonvulsants; Mood lability; Gabapentin **49,** 229

Borderline; Depression; Suicide; Personality **49,** 151

Case register; Affective disorder; Unipolar; Bipolar; Longitudinal data; Recurrence; Predictors **49,** 101

Citalopram; Social phobia; Serotonin **49,** 79

Citalopram; Depressive patients; SSRI; Infusion; Pharmacokinetics **49,** 203

Clinical trials; Light; Antidepressant; Depression **49,** 109

Cognitive therapy; Behaviour therapy; Depression; Meta-analysis; Psychotherapy; Antidepressants **49,** 59

Consultations; Seasonal affective disorder; Primary care **49,** 1

Cordance; Major depression; Late life depression; Physiology; EEG **49,** 89

Cortisol; Suicide attempt; Affective disorders; Temperament; Neuropeptides; Dexamethasone suppression test **49,** 45

Cortisol; Lamotrigine; Serotonin, 5-HT_{1A} receptors; Ipsapirone; Hypothermia **49,** 157

Course of illness; Bipolar disorder; Gender differences; Depression; Well-being and functioning; Outcome; Physical health; Pain **49,** 189

C-reactive protein; Affective disorders; Acute phase proteins; Transferrin **49,** 9

Cross sectional survey; Pharmacoepidemiology; Antidepressant; General population; Prescription; Drug utilization review **49,** 19

Cytokines; Tryptophan; Amino acids; PGE2; Depression; Sleep disorders **49,** 211

Depression; Mood disorder; Insight; Mania **49,** 55

Depression; Cognitive therapy; Behaviour therapy; Meta-analysis; Psychotherapy; Antidepressants **49,** 59

Depression; Folate; Inpatients **49,** 73

Depression; Light; Antidepressant; Clinical trials **49,** 109

S0165-0327(98)00045-7

Depression; Infradian mood fluctuations; Fluvoxamine **49,** 133

Depression; SSRI; Antidepressants; Treatment **49,** 141

Depression; Suicide; Borderline; Personality **49,** 151

Depression; Bipolar disorder; Gender differences; Well-being and functioning; Course of illness; Outcome; Physical health; Pain **49,** 189

Depression; Tryptophan; Amino acids; Cytokines; PGE2; Sleep disorders **49,** 211

Depression; Lithium; Thyroxine; Augmentation **49,** 235

Depressive mood disorders; Mental disorder; Sleep; Polysomnography **49,** 27

Depressive patients; SSRI; Citalopram; Infusion; Pharmacokinetics **49,** 203

Dexamethasone suppression test; Suicide attempt; Affective disorders; Temperament; Neuropeptides; Cortisol **49,** 45

Drug utilization review; Pharmacoepidemiology; Antidepressant; General population; Cross sectional survey; Prescription **49,** 19

EEG; Major depression; Late life depression; Physiology; Cordance **49,** 89

Fluvoxamine; Infradian mood fluctuations; Depression **49,** 133

Folate; Inpatients; Depression **49,** 73

Gabapentin; Bipolar disorder; Treatment; Anticonvulsants; Mood lability **49,** 229

Gender differences; Bipolar disorder; Depression; Well-being and functioning; Course of illness; Outcome; Physical health; Pain **49,** 189

General population; Pharmacoepidemiology; Antidepressant; Cross sectional survey; Prescription; Drug utilization review **49,** 19

Hypothermia; Lamotrigine; Serotonin, 5-HT_{1A} receptors; Ipsapirone; Cortisol **49,** 157

Infradian mood fluctuations; Depression; Fluvoxamine **49,** 133

Infusion; Depressive patients; SSRI; Citalopram; Pharmacokinetics **49,** 203

Inpatients; Folate; Depression **49,** 73

Insight; Mood disorder; Mania; Depression **49,** 55

Ipsapirone; Lamotrigine; Serotonin, 5-HT_{1A} receptors; Hypothermia; Cortisol **49,** 157

Lamotrigine; Serotonin, 5-HT_{1A} receptors; Ipsapirone; Hypothermia; Cortisol **49,** 157

Late life depression; Major depression; Physiology; EEG; Cordance **49,** 89

Light; Antidepressant; Depression; Clinical trials **49,** 109

Lithium; Depression; Thyroxine; Augmentation **49,** 235

Longitudinal data; Affective disorder; Unipolar; Bipolar; Case register; Recurrence; Predictors **49,** 101

Maintenance; Recurrence prevention; Treatment strategies **49,** 31

Major depression; Late life depression; Physiology; EEG; Cordance **49,** 89

Major depression; Antidepressant response; Sleep; Arousal-analysis **49,** 221

Mania; Mood disorder; Insight; Depression **49,** 55

Mental disorder; Depressive mood disorders; Sleep; Polysomnography **49,** 27

Meta-analysis; Cognitive therapy; Behaviour therapy; Depression; Psychotherapy; Antidepressants **49,** 59

Mood disorder; Insight; Mania; Depression **49,** 55

Mood lability; Bipolar disorder; Treatment; Anticonvulsants; Gabapentin **49,** 229

Neuropeptides; Suicide attempt; Affective disorders; Temperament; Dexamethasone suppression test; Cortisol **49,** 45

Neuropsychology; Panic disorder; Anxiety **49,** 123

Newcastle rating scale; Unipolar; Bipolar I; Bipolar II major depression; Sleep EEG data; REM-sleep; REM-latency **49,** 181

Olanzapine; Bipolar disorder **49,** 119

Outcome; Bipolar disorder; Gender differences; Depression; Well-being and functioning; Course of illness; Physical health; Pain **49,** 189

Pain; Bipolar disorder; Gender differences; Depression; Well-being and functioning; Course of illness; Outcome; Physical health **49,** 189

Panic disorder; Neuropsychology; Anxiety **49,** 123

Personality; Depression; Suicide; Borderline **49,** 151

PGE2; Tryptophan; Amino acids; Cytokines; Depression; Sleep disorders **49,** 211

Pharmacoepidemiology; Antidepressant; General population; Cross sectional survey; Prescription; Drug utilization review **49,** 19

Pharmacokinetics; Depressive patients; SSRI; Citalopram; Infusion **49,** 203

Physical health; Bipolar disorder; Gender differences; Depression; Well-being and functioning; Course of illness; Outcome; Pain **49,** 189

Physiology; Major depression; Late life depression; EEG; Cordance **49,** 89

Polysomnography; Mental disorder; Depressive mood disorders; Sleep **49,** 27

Postpartum depression; Risk factors; Pregnancy; Predictive signs **49,** 167

Predictive signs; Postpartum depression; Risk factors; Pregnancy **49,** 167

Predictors; Affective disorder; Unipolar; Bipolar; Case register; Longitudinal data; Recurrence **49,** 101

Pregnancy; Postpartum depression; Risk factors; Predictive signs **49,** 167

Prescription; Pharmacoepidemiology; Antidepressant; General population; Cross sectional survey; Drug utilization review **49,** 19

Primary care; Seasonal affective disorder; Consultations **49,** 1

Psychotherapy; Cognitive therapy; Behaviour therapy; Depression; Meta-analysis; Antidepressants **49,** 59

Recurrence; Affective disorder; Unipolar; Bipolar; Case register; Longitudinal data; Predictors **49,** 101

Recurrence prevention; Maintenance; Treatment strategies **49,** 31

REM-latency; Unipolar; Bipolar I; Bipolar II major depression; Sleep EEG data; Newcastle rating scale; REM-sleep **49,** 181

REM-sleep; Unipolar; Bipolar I; Bipolar II major depression; Sleep EEG data; Newcastle rating scale; REM-latency **49,** 181

Risk factors; Postpartum depression; Pregnancy; Predictive signs **49,** 167

SAD; Tropical climate; Absent atypical vegetative symptoms **49,** 145

Seasonal affective disorder; Primary care; Consultations **49,** 1

Serotonin; Social phobia; Citalopram **49,** 79

Serotonin, 5-HT$_{1A}$ receptors; Lamotrigine; Ipsapirone; Hypothermia; Cortisol **49,** 157

Sleep; Mental disorder; Depressive mood disorders; Polysomnography **49,** 27

Sleep; Major depression; Antidepressant response; Arousalanalysis **49,** 221

Sleep disorders; Tryptophan; Amino acids; Cytokines; PGE2; Depression **49,** 211

Sleep EEG data; Unipolar; Bipolar I; Bipolar II major depression; Newcastle rating scale; REM-sleep; REM-latency **49,** 181

Social phobia; Citalopram; Serotonin **49,** 79

SSRI; Depression; Antidepressants; Treatment **49,** 141

SSRI; Depressive patients; Citalopram; Infusion; Pharmacokinetics **49,** 203

Suicide; Depression; Borderline; Personality **49,** 151

Suicide attempt; Affective disorders; Temperament; Neuropeptides; Dexamethasone suppression test; Cortisol **49,** 45

Temperament; Suicide attempt; Affective disorders; Neuropeptides; Dexamethasone suppression test; Cortisol **49,** 45

Thyroxine; Depression; Lithium; Augmentation **49,** 235

Transferrin; Affective disorders; Acute phase proteins; C-reactive protein **49,** 9

Treatment; Depression; SSRI; Antidepressants **49,** 141

Treatment; Bipolar disorder; Anticonvulsants; Mood lability; Gabapentin **49,** 229

Treatment strategies; Recurrence prevention; Maintenance **49,** 31

Tropical climate; SAD; Absent atypical vegetative symptoms **49,** 145

Tryptophan; Amino acids; Cytokines; PGE2; Depression; Sleep disorders **49,** 211

Unipolar; Affective disorder; Bipolar; Case register; Longitudinal data; Recurrence; Predictors **49,** 101

Unipolar; Bipolar I; Bipolar II major depression; Sleep EEG data; Newcastle rating scale; REM-sleep; REM-latency **49,** 181

Well-being and functioning; Bipolar disorder; Gender differences; Depression; Course of illness; Outcome; Physical health; Pain **49,** 189